Joie N. Marhefka
University of Pittsburgh
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Joie N. Marhefka.
Biorheology | 2010
R Zhao; Joie N. Marhefka; James F. Antaki; Marina V. Kameneva
The accumulation of platelets near the blood vessel wall or artificial surface is an important factor in the cascade of events responsible for coagulation and/or thrombosis. In small blood vessels and flow channels this phenomenon has been attributed to the blood phase separation that creates a red blood cell (RBC)-poor layer near the wall. We hypothesized that blood soluble drag-reducing polymers (DRP), which were previously shown to lessen the near-wall RBC depletion layer in small channels, may consequently reduce the near-wall platelet excess. This study investigated the effects of DRP on the lateral distribution of platelet-sized fluorescent particles (diam. = 2 μm, 2.5 × 10⁸/ml) in a glass square microchannel (width and depth = 100 μm). RBC suspensions in PBS were mixed with particles and driven through the microchannel at flow rates of 6-18 ml/h with and without added DRP (10 ppm of PEO, MW = 4500 kDa). Microscopic flow visualization revealed an elevated concentration of particles in the near-wall region for the control samples at all tested flow rates (between 2.4 ± 0.8 times at 6 ml/h and 3.3 ± 0.3 times at 18 ml/h). The addition of a minute concentration of DRP virtually eliminated the near-wall particle excess, effectively resulting in their even distribution across the channel, suggesting a potentially significant role of DRP in managing and mitigating thrombosis.
Biorheology | 2008
Joie N. Marhefka; Sachin S. Velankar; Toby M. Chapman; Marina V. Kameneva
Natural and synthetic soluble drag reducing polymers (DRP) have been shown to produce beneficial effects on blood circulation in various animal models and may represent a novel bioengineering way to treat cardiovascular disorders. These polymers are known to degrade when subjected to high shear stresses which could be a part of the process of their elimination from the vascular system. However, the relative rate of their degradation was not known especially in the presence of blood cells or particles. The hydrodynamic tests in this study demonstrated that DRP mechanical degradation was significantly increased by the presence of red blood cells (RBC) and even more so by the presence of rigid particles of similar size. Degradation rates increased with an increase in RBC or particle concentration. The natural DRP (derived from aloe) was shown to be much more resistant to flow-induced degradation than polyethylene oxide in the presence or absence of RBC.
ASME 2007 Summer Bioengineering Conference | 2007
Rui Zhao; Joie N. Marhefka; Marina V. Kameneva; James F. Antaki
Thrombosis is a common complication associated with blood contacting devices [1]. Platelets often (or preferably) deposit in specific regions which contain complex flow featuring separations, recirculation zones and stagnation points [2, 3].Copyright
Asaio Journal | 2005
Joie N. Marhefka; Philip J. Marascalco; Toby M. Chapman; Marina V. Kameneva
Water-soluble drag-reducing polymers (DRPs) were previously demonstrated to significantly increase blood flow, tissue perfusion, and tissue oxygenation when injected intravenously at nanomolar concentrations in various animal models. Turbulent flow drag-reducing ability was proven to be the most important factor defining the potential of polymers to favorably affect blood circulation. Several DRPs were applied in previous in vivo tests, but the search continues for suitable DRPs for biomedical applications. We demonstrated that poly(N-vinylformamide) (PNVF) with a molecular weight of 4.5 x 10(6) Da significantly reduced resistance to turbulent flow in a pipe and thus presents a DRP. We also found that the PNVF mechanical degradation is much slower than that of the most commonly used DRP, poly(ethylene oxide). PNVF is known to have low toxicity. Furthermore, our pilot in vivo study showed that PNVF had acceptable biocompatibility and hemodynamic effectiveness and thus could be considered as a DRP candidate for potential clinical use.
Annals of Biomedical Engineering | 2008
Rui Zhao; Joie N. Marhefka; Fangjun Shu; Samuel J. Hund; Marina V. Kameneva; James F. Antaki
Biorheology | 2009
Joie N. Marhefka; Rui Zhao; Zhongjun J. Wu; S.S. Velankar; James F. Antaki; Marina V. Kameneva
Biomacromolecules | 2006
Joie N. Marhefka; Philip J. Marascalco; Toby M. Chapman; Alan J. Russell; Marina V. Kameneva
Asaio Journal | 2006
Philip J. Marascalco; Sean Ritchie; Joie N. Marhefka; Marina V. Kameneva
Bioorganic & Medicinal Chemistry Letters | 2006
Qun Li; Guisheng Zhang; Joie N. Marhefka; Marina V. Kameneva; Dexi Liu
International Journal of Engineering Science | 2014
Joie N. Marhefka; Paula F. Moon-Massat; Gregory P. Dubé; William R. Light; Daniel Freilich; Alan J. Russell; Marina V. Kameneva